Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  ImmunoGen, Inc.    IMGN

Delayed Quote. Delayed  - 09/23 10:00:00 pm
2.82 USD   -1.74%
08/09 IMMUNOGEN : Announces Departure of Chief Development Officer
08/05 IMMUNOGEN, INC. : Announces Webcasts of Presentations at Upcoming In..
08/04 IMMUNOGEN : reports 4Q loss
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

FDA Approves Kadcyla, Breast-Cancer Drug from Roche, ImmunoGen

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/22/2013 | 05:26pm CEST
   By Jennifer Corbett Dooren 
 

WASHINGTON--The U.S. Food and Drug Administration Friday approved a powerful new type of drug that will be marketed by Roche Holding AG (ROG.VX, RHHBY) to treat breast cancer.

The drug called, Kadcyla, combines Roche's existing cancer drug, Herceptin, with a powerful chemotherapy agent.

Herceptin targets a protein called HER2 found on tumors in about 20% to 25% of breast-cancer patients. The two other components of Kadcyla, both developed by ImmunoGen Inc. (>> ImmunoGen, Inc.), are a chemotherapy agent called emtansine that is too potent to be delivered as a conventional medicine, and a linker that connects the two drugs. Herceptin then delivers the package to the tumor cell, where it releases the toxic cargo to kill the cancer.

The FDA's approval of Kadcyla, which was previously known as T-DM1, triggers a $10.5 million payment to ImmunoGen by Roche. ImmunoGen will also receive royalties on sales.

Roche's Genentech unit said Kadcyla will be available to patients in about two weeks. The drug will be priced at $9,800 a month. The company said there will be a patient-assistance program to help pay for the product.

The approval of Kadcyla was based on a study of about 1,000 women with HER2-positive breast cancer who had been treated previously with Herceptin and a traditional chemotherapy drug. About half of the women were then treated with T-DM1 and the other half were treated with a combination of Xeloda, another Roche drug, and GlaxoSmithKline PLC's (GSK, GSK.LN) Tykerb. The drugs were administered every three weeks until the disease progressed or patients experienced unmanageable side effects.

The study was designed to measure progression-free survival, which is a measurement of the time from the start of treatment until the disease gets worse or the patient dies, and overall survival, which is a measurement of time from the start of treatment until death.

The median progression-free survival for patients receiving T-DM1 was 9.6 months, compared with 6.4 months in the group receiving Xeloda and Tykerb, a difference considered statistically significant. The median overall survival was 30.9 months in the Kadcyla group and 25.1 months for Xeloda and Tykerb group.

Write to Jennifer Corbett Dooren at jennifer.corbett@dowjones.com.

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : ImmunoGen, Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IMMUNOGEN, INC.
09/16 IMMUNOGEN INC : Change in Directors or Principal Officers (form 8-K)
09/15 IMMUNOGEN : New Oligopeptides Study Findings Recently Were Reported by Researche..
09/09 IMMUNOGEN : Patent Issued for Preparation of Maytansinoid Antibody Conjugates by..
08/25 IMMUNOGEN : Management's Discussion and Analysis of Financial Condition and Resu..
08/25 IMMUNOGEN INC : Results of Operations and Financial Condition (form 8-K)
08/17 IMMUNOGEN INC : Change in Directors or Principal Officers, Financial Statements ..
08/09 IMMUNOGEN INC : Change in Directors or Principal Officers, Financial Statements ..
08/09 IMMUNOGEN : Announces Departure of Chief Development Officer
08/05 IMMUNOGEN, INC. : Announces Webcasts of Presentations at Upcoming Investor Confe..
08/04 IMMUNOGEN : reports 4Q loss
More news
Sector news : Biotechnology & Medical Research - NEC
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
09/21DJGILEAD SCIENCES : Halts Test of Bowel Disease Treatment
09/20 Bayer raises sales targets for top-selling drugs after Monsanto deal
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
08/24 Best And Worst Performing Stocks Of 2016
08/04 ImmunoGen's (IMGN) CEO Dan Junius on Q4 2016 Results - Earnings Call Transcri..
08/04 ImmunoGen, Inc. 2016 Q2 - Results - Earnings Call Slides
08/04 PREMARKET GAINERS / LOSERS AS OF 9 : 10 am
08/04 ImmunoGen misses by $0.12, misses on revenue
Advertisement
Financials ($)
Sales 2017 76,1 M
EBIT 2017 -121 M
Net income 2017 -148 M
Debt 2017 133 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 4,98x
EV / Sales 2018 4,81x
Capitalization 246 M
More Financials
Chart IMMUNOGEN, INC.
Duration : Period :
ImmunoGen, Inc. Technical Analysis Chart | IMGN | US45253H1014 | 4-Traders
Full-screen chart
Technical analysis trends IMMUNOGEN, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 8,29 $
Spread / Average Target 194%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mark J. Enyedy President, Chief Executive Officer & Director
Stephen C. McCluski Chairman
David B. Johnston Chief Financial Officer & Executive Vice President
Richard J. Gregory Chief Scientific Officer & Executive VP
Joseph J. Villafranca Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOGEN, INC.-79.22%246
INCYTE CORPORATION-17.95%16 728
CELLTRION, INC.--.--%11 664
LONZA GROUP AG13.18%10 059
QUINTILES TRANSNATIONA..15.66%9 453
SEATTLE GENETICS, INC.24.40%7 845
More Results